Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Research analysts at HC Wainwright upped their Q1 2025 EPS estimates for Atossa Therapeutics in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.05) per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.30) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.18) EPS.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Separately, Ascendiant Capital Markets upped their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th.

Atossa Therapeutics Trading Up 0.3 %

Shares of NASDAQ ATOS opened at $0.70 on Friday. Atossa Therapeutics has a one year low of $0.66 and a one year high of $2.31. The business has a 50-day moving average price of $0.79 and a two-hundred day moving average price of $1.11. The firm has a market capitalization of $87.88 million, a PE ratio of -3.18 and a beta of 1.20.

Hedge Funds Weigh In On Atossa Therapeutics

Hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in shares of Atossa Therapeutics by 30.7% during the 4th quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock worth $68,000 after acquiring an additional 16,853 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Atossa Therapeutics during the 3rd quarter worth about $29,000. Barclays PLC boosted its stake in Atossa Therapeutics by 14.5% during the 4th quarter. Barclays PLC now owns 191,954 shares of the company’s stock valued at $181,000 after purchasing an additional 24,236 shares during the period. XTX Topco Ltd grew its holdings in Atossa Therapeutics by 101.2% in the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after buying an additional 24,951 shares during the last quarter. Finally, Gallagher Capital Advisors LLC acquired a new stake in Atossa Therapeutics in the 4th quarter valued at approximately $25,000. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.